Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
PaperCitations, authors & open-access status
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 334 citations, 2019 year and closed oa status.
334
Citations
2019
Year
closed
OA Status